A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi mieć nowotwór z widocznymi zmianami podczas badań obrazowych.
- •Ogólny stan zdrowia pacjenta musi pozwalać na normalną aktywność lub wymagać niewielkiej pomocy (skala ECOG 0 lub 1).
- •Przewidywana długość życia pacjenta musi wynosić co najmniej 3 miesiące od rozpoczęcia leczenia.
- •Grupa A, B, E: Pacjent musi mieć potwierdzonego raka płuca typu NSCLC, który jest zaawansowany lub rozsiany, z określonymi mutacjami w genie EGFR.
- •Grupa C, D: Pacjent musi mieć potwierdzonego potrójnie ujemnego raka piersi (TNBC) lub raka piersi (BC) z niskim poziomem estrogenów i negatywnym HER2, który jest zaawansowany, nawrotowy, nieoperacyjny lub rozsiany.
✗ Disqualifies
- •Pacjent nie może mieć mieszanego typu raka płuca (SCLC i NSCLC).
- •Pacjenci z niektórymi znanymi mutacjami w genie EGFR (dotyczy grup A, B, E) nie mogą brać udziału.
- •Pacjent nie może mieć historii ciężkich nawracających infekcji.
- •Pacjent nie może mieć historii poważnych chorób serca.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (64)
University of Alabama at Birmingham
Birmingham, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami, United States
Local Institution - 0125
Maywood, United States
Local Institution - 0065
Iowa City, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, United States
Cleveland Clinic
Cleveland, United States
Local Institution - 0102
Columbus, United States
Local Institution - 0134
Portland, United States
Local Institution - 0052
Portland, United States
Local Institution - 0090
Portland, United States
Local Institution - 0014
Pittsburgh, United States
University of Tennessee Medical Center
Knoxville, United States
NEXT Oncology - Irving
Irving, United States
Swedish Medical Center
Seattle, United States
Liverpool Hospital
Liverpool, Australia
Princess Alexandra Hospital
Woolloongabba, Australia
Local Institution - 0108
East Melbourne, Australia
Local Institution - 0101
Subiaco, Australia
Cross Cancer Institute
Edmonton, Canada
Local Institution - 0064
Newmarket, Canada
Local Institution - 0023
Ottawa, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Canada
Jewish General Hospital
Montreal, Canada
Local Institution - 0105
Valdivia, Chile
Local Institution - 0048
Santiago, Chile
Local Institution - 0049
Santiago, Chile
Local Institution - 0047
Santiago, Chile
Local Institution - 0107
Viña del Mar, Chile
Local Institution - 0077
Nice, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
Bordeaux, France
Centre Leon Berard
Lyon, France
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, France
Local Institution - 0076
Caen, France
Hôpital Arnaud de Villeneuve - CHU Montpellier
Montpellier, France
Gustave Roussy
Villejuif, France
Institut Curie
Paris, France
Hôpital Tenon
Paris, France
Cro-Irccs
Aviano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
Candiolo, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Local Institution - 0110
Ancona, Italy
Local Institution - 0093
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, Italy
Leids Universitair Medisch Centrum
Leiden, Netherlands
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)
Amsterdam, Netherlands
CHUS - Hospital Clinico Universitario
Santiago de Compostela, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Institut Català d'Oncologia - L'Hospitalet
Hospitalet, Spain
Local Institution - 0059
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Spain
Local Institution - 0118
Valencia, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Local Institution - 0127
Madrid, Spain
Hospital Universitario HM Sanchinarro
Madrid, Spain
H.R.U Málaga - Hospital General
Málaga, Spain
Local Institution - 0112
Seville, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Royal Free Hospital
London, United Kingdom
Local Institution - 0021
Glasgow, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
Local Institution - 0001
Newcastle upon Tyne, United Kingdom
Trial contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
First line of the email MUST contain NCT # and Site #.
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.